BVS — Bioventus Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1665988 ·
Last close
$8.60
Market Cap
$582.63M
52W High
$11.25
52W Low
$7.81
ADV30
670,049
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 132,089,000 | 90,769,000 | 8,870,000 | 3,113,000 | 650,539,000 | 35,846,000 | 416,274,000 |
| Dec 2025 | 157,900,000 | 108,782,000 | 21,721,000 | 14,755,000 | 683,559,000 | 51,238,000 | 455,112,000 |
| Sep 2025 | 138,651,000 | 94,229,000 | 11,251,000 | 3,155,000 | 701,593,000 | 42,164,000 | 494,338,000 |
| Jun 2025 | 147,660,000 | 102,090,000 | 18,369,000 | 7,459,000 | 706,788,000 | 32,910,000 | 505,489,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$74,673,000
Investing CF
$-3,248,000
Financing CF
$-62,140,000
CapEx
$-2,562,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.33
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,929,000
Inventory
$82,236,000
Receivables
$128,303,000
ST Investments
—
EBIT TTM
$52,195,000
Pretax Income TTM
$25,709,000
Interest Exp TTM
$26,486,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$576,300,032
EBITDA
$80,897,000
Free Cash Flow
$63,310,876
Enterprise Value
$880,571,200
Total Cash
$35,846,000
Total Debt
$288,420,000
Shares Out
67,748,048
Trailing EPS
$0.41
Book Value
$2.79
ROE
16.5%
ROA
5.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 568,087,000 | 56,291,000 | 22,732,000 | 683,559,000 | 455,112,000 | — | 74,673,000 |
| Dec 2024 | 573,280,000 | 22,825,000 | -36,125,000 | 727,956,000 | 542,352,000 | — | 38,795,000 |
| Dec 2023 | 512,345,000 | 2,026,000 | -156,230,000 | 810,910,000 | 589,792,000 | — | 15,344,000 |
| Dec 2022 | 512,117,000 | -34,656,000 | -158,704,000 | 1,372,649,000 | 960,427,000 | — | -13,537,000 |
TTM Snapshot
Revenues TTM
$138,964,000
NetIncome TTM
$-5,165,000
OpCashFlow TTM
$0
Assets (Latest)
$727,956,000
Forward EPS
$0.91
Max Pain — expiry 2026-07-17
max pain strike: $7.50 · spot: $8.72 · call oi: 1,433 · put oi: 429
Expected Move to 2026-07-17:
±$1.53
(17.60%) —
implied range
$7.19 –
$10.26
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BWAY | Brainsway Ltd. | $574.54M | $14.33 | — |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | $594.58M | $26.36 | — |
| MDXG | MIMEDX GROUP, INC. | $548.12M | $3.68 | — |
| SGP | SpyGlass Pharma, Inc. | $633.23M | $18.94 | — |
| BBNX | Beta Bionics, Inc. | $640.80M | $14.38 | — |
News headlines (Yahoo Finance, 1h cache)
Are Investors Undervaluing Bioventus (BVS) Right Now?
2026-06-09 13:40 · Yahoo
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
2026-06-08 23:03 · Yahoo
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
2026-06-03 13:40 · Yahoo
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)
2026-06-02 13:35 · Yahoo
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
2026-06-02 11:00 · Yahoo
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
2026-05-29 13:55 · Yahoo
Is Bioventus (BVS) Stock Undervalued Right Now?
2026-05-21 13:40 · Yahoo
Are Medical Stocks Lagging Bioventus (BVS) This Year?
2026-05-18 13:40 · Yahoo
Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next
2026-05-14 15:47 · Yahoo
Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors
2026-05-14 12:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.